Responses
Immunotherapy biomarkers
Original research
Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
Compose a Response to This Article
Other responses
No responses have been published for this article.
